

I never think of the future, it comes soon enough. A Einstein

**Disease-based → Individualized**

**Recognition of interim FDG PET as a potential surrogate for chemosensitivity laid groundwork for response-adapted therapy trials**

**Risk-adapted → Response-adapted ?**

- Subjectivity is the Achilles heel of visual iPET reading; many published iPET results lacked consistent/std criteria
- To fulfill this need, a graded method of visual criteria were proposed at an international meeting held in Deauville, 2009

Meignan M, Leuk Lymphoma. 2009;50:1257

### Deauville 5-point scale

#### NEGATIVE

De-esc  
FN ↓

Esc  
FP ↓

Score 1 no uptake

Score 2 uptake  $\leq$  mediastinum

Score 3 uptake  $>$  mediastinum  $\leq$  liver

#### POSITIVE

Score 4: moderately  $\uparrow$  uptake  $>$  liver

Score 5 markedly  $\uparrow$  uptake  $>$  liver

- Two independent international validation studies (IVS) launched to validate the proposed 5-p scale to establish reproducibility and the predictive role of interim PET in HL and DLBCL
- Role of SUVs were also investigated in the DLBCL study

Itti E, J Nucl Med. 2009;50:527

**Deauville Criteria for the Assessment of Interim PET  
in Advanced Stage Hodgkin Lymphoma Patients  
Enrolled in the International Validation Study Study.**

A Gallamini, et al

**International Validation Study of the Deauville  
Criteria for Interim FDG PET/CT Interpretation in  
Diffuse Large B-Cell Lymphoma.**

E Itti, et al

## Pressing Questions (imaging community)

1. Are we ready to introduce the routine clinical use of interim PET and Deauville 5-PS interpretation criteria for HL ?
2. Are we ready to introduce the routine clinical use of interim PET and Deauville 5-PS interpretation criteria for DLBCL ?

## Pressing Questions (clinicians)

1. Was the predictive value of interim PET confirmed by the IVS study with sufficiently robust data in HL patients ?
2. Was the predictive value of interim PET confirmed by the IVS study with sufficiently robust data in DLBCL patients?